Top Markets
Coin of the day
Orient EuroPharma Co., Ltd. Orient EuroPharma Co., Ltd.

Orient EuroPharma Co., Ltd.

4120
Xếp hạng trong cổ phiếu #20422
Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical... Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, such as cardiovascular issues, metabolic disorders, neurological ailments, obstetric and gynecological health, respiratory diseases, andrological concerns, immunological responses, as well as antibiotics and anti-cancer therapies. Beyond prescription drugs, the company offers nutritional and infant care items, including specialized milk formulas and dietary supplements, marketed under the brand names Karihome, Babecare, and Ostricare. Additionally, it supplies health-related supplements, notably Buccotherm-branded thermal water, designed for the management of oral and periodontal conditions. The company's diverse product range extends to skincare, featuring items like essences, creams, lotions, eye creams, facial toners, and skin-repairing treatments available through its AGLab line. It also distributes skincare oils, body lotions, and gels for dry skin under the well-known Bio-Oil brand, and markets children's skincare solutions through the Mister Baby brand. Furthermore, OEP oversees ISISPHARMA, a dermatology laboratory dedicated to the creation and distribution of specialized dermo-cosmetic goods. Orient EuroPharma is actively involved in extensive research and development efforts, with several key compounds in its pipeline. These include Multikine, an immunotherapy treatment for head and neck cancer currently undergoing Phase III clinical trials; NC-6004, a platinum-based micelle chemotherapeutic agent also in Phase III; ASC-J9, a molecular chemical entity targeting androgen receptor degradation, which has successfully finished its Phase IIb clinical study; and 2ccPA, a phospholipid derivative for symptomatic knee osteoarthritis, progressing through Phase I clinical trials. Established in 1982, Orient EuroPharma Co., Ltd. maintains its headquarters in Taipei, Taiwan.
Giá cổ phiếu
$1.51
Vốn hóa thị trường
$131.03M
Thay đổi (1 ngày)
-0.84%
Thay đổi (1 năm)
-11.75%
Quốc gia
TW
Giao dịch Orient EuroPharma Co., Ltd. (4120)

Danh mục

Lịch sử chia tách cổ phiếu của Orient EuroPharma Co., Ltd. (4120)
Cổ phiếu Orient EuroPharma Co., Ltd. (mã: 4120) đã trải qua tổng cộng 0 lần chia tách.
Lần chia tách gần nhất diễn ra vào ngày Aug 24, 2026.
Một cổ phiếu 4120 mua trước ngày Aug 24, 2026 hiện tương đương với 0 cổ phiếu 4120.
Danh sách chia tách cổ phiếu
Năm Chia tách Tỷ lệ Tỷ lệ cộng dồn
Không đủ dữ liệu cho ngày được cung cấp.
Chia tách cổ phiếu của các công ty tương tự hoặc đối thủ
Công ty Số lần chia tách cổ phiếu Tỷ lệ cộng dồn Quốc gia
0 -
DE
0 -
DE
0 -
JP
0 -
CH
5 x119
IN